PFE kept non-GAAP EPS guidance for 2011-2012 unchanged following today’s 2Q11 report. The ranges are as follows:
2011: $2.16-2.26 2012: $2.25-$2.35
The midpoint of the 2012 range represents a P/E of only 8x. Hence, investors must be thinking that either: i) the 2012 EPS range won’t be met; or ii) there will be negative EPS growth in the period starting in 2013. I don’t think either i) or ii) will come to pass, so it follows that I consider PFE a pretty good buy at the current price.
As has been stated ad nauseam (e.g. #msg-59590951), PFE is a strong beneficiary of The Global Demographic Tailwind. PFE’s 2Q11 sales in emerging markets had an annualized rate of about $13B, which is roughly 20% of PFE’s overall sales. 2Q11 sales in emerging markets grew strongly year-over-year despite the loss of patent protection in some countries on such key brands such as Lipitor and Viagra.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.